LPTX - LEAP THERAPEUTICS, INC.
IEX Last Trade
2.87
-0.030 -1.045%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:28:28 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$2.90
-0.03
-1.03%
Fundamental analysis
29%
Profitability
43%
Dept financing
15%
Liquidity
50%
Performance
15%
Performance
5 Days
0 0%
1 Month
15.48%
3 Months
11.49%
6 Months
59.89%
1 Year
-10.19%
2 Year
519.15%
Key data
Stock price
$2.87
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.79 - $5.00
52 WEEK CHANGE
-$34.31
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Doug E. Onsi
Region: US
Website: leaptx.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: leaptx.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Leap Therapeutics, Inc. acquires and develops therapies for the treatment of cancer. DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
Recent news